

– 42 –

WHAT IS CLAIMED IS:

1. A method for preventing, treating, or ameliorating restenosis after angioplasty or stenosis after arterial bypass surgery in an animal, comprising administering to the animal a therapeutically effective amount of an active vitamin D compound.
2. The method of claim 1, wherein said angioplasty occurred in a coronary artery, a peripheral artery, or a bypass graft.
3. The method of claim 1, wherein said arterial bypass surgery occurred in a coronary artery or a peripheral artery.
4. The method of claim 1, further comprising inserting a stent during or after the angioplasty.
5. The method of claim 1, wherein said active vitamin D compound is administered before the angioplasty or bypass surgery.
6. The method of claim 1, wherein said active vitamin D compound is administered after the angioplasty or bypass surgery.
7. The method of claim 1, wherein said active vitamin D compound is administered before and after the angioplasty or bypass surgery.
8. The method of claim 1, wherein said active vitamin D compound is calcitriol.
9. The method of claim 1, wherein said active vitamin D compound has a reduced hypercalcemic effect.

– 43 –

10. The method of claim 9, wherein said active vitamin D compound is selected from the group consisting of EB 1089, Ro23-7553, and Ro24-5531.

11. The method of claim 1, wherein said active vitamin D compound is administered daily at a dose of about 0.5 µg to about 5 µg.

12. The method of claim 1, wherein said active vitamin D compound is administered by high dose pulse administration (HDPA), wherein each pulsed dose is a sufficient amount to have a therapeutic effect.

13. The method of claim 12, wherein said HDPA is administered no more frequently than once in three days.

14. The method of claim 13, wherein said HDPA is administered no more frequently than once in four days.

15. The method of claim 14, wherein said HDPA is administered no more frequently than once a week.

16. The method of claim 12, wherein said active vitamin D compound is administered at a dose of about 3 µg to about 300 µg.

17. The method of claim 16, wherein said active vitamin D compound is administered at a dose of about 15 µg to about 260 µg.

18. The method of claim 17, wherein said active vitamin D compound is administered at a dose of about 30 µg to about 240 µg.

19. The method of claim 18, wherein said active vitamin D compound is administered at a dose of about 50 µg to about 220 µg.

— 44 —

20. The method of claim 19, wherein said active vitamin D compound is administered at a dose of about 75  $\mu\text{g}$  to about 200  $\mu\text{g}$ .

21. The method of claim 12, wherein said active vitamin D compound is administered at a dose sufficient to obtain a peak plasma concentration of the active vitamin D compound of at least 0.5 nM.

22. The method of claim 1, wherein said active vitamin D compound is administered orally, intravenously, parenterally, rectally, topically, nasally or transdermally.

23. The method of claim 22, wherein said active vitamin D compound is administered orally.

24. The method of claim 22, wherein said active vitamin D compound is administered intravenously.

25. The method of claim 1, further comprising administering one or more therapeutic agents.

26. The method of claim 25, wherein said one or more therapeutic agents are selected from the group consisting of antineoplastic agents, vasodilators, anticoagulants, anti-platelet agents, anti-thrombins, immunosuppressants, anti-inflammatories, and collagen synthetase inhibitors.

27. The method of claim 25, wherein said one or more therapeutic agents are selected from the group consisting of actinomycin D, irinotecan, vincristine, vinblastine, methotrexate, azathioprine, fluorouracil, doxorubicin, mitomycin, nitrates, calcium channel blockers, heparin, aspirin, blockers of IIb/IIIa receptors, hirudin, iloprost, sirolimus, everolimus, A24, tranilast, dexamethasone, tacrolimus, halofuginone, propyl hydroxylase, C-proteinase inhibitor, metalloproteinase inhibitor, corticosteroids, non-steroidal anti-

– 45 –

inflammatory drugs, 17 $\beta$ -estradiol, angiotensin converting enzyme inhibitors, colchicine, fibroblast growth factor antagonists, histamine antagonists, lovastatin, nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, thioprotease inhibitors, platelet-derived growth factor antagonists, nitric oxide, and angiopeptin.

28. The method of claim 25, wherein said one or more therapeutic agents is a taxane.

29. The method of claim 28, wherein said taxane is paclitaxel or docetaxel.

30. The method of claim 25, wherein said one or more therapeutic agents are administered before the active vitamin D compound.

31. The method of claim 25, wherein said one or more therapeutic agents are administered concurrently with the active vitamin D compound.

32. The method of claim 25, wherein said one or more therapeutic agents are administered after the active vitamin D compound.

33. The method of claim 1, wherein said active vitamin D compound is administered as a unit dosage form comprising about 10  $\mu$ g to about 75  $\mu$ g of calcitriol, about 50% MIGLYOL 812 and about 50% tocopherol PEG-1000 succinate (vitamin E TPGS).

34. The method of claim 33, wherein said unit dosage form comprises about 45  $\mu$ g of calcitriol.

35. The method of claim 33, wherein said unit dosage form further comprises at least one additive selected from the group consisting of an antioxidant, a bufferant, an antifoaming agent, a detackifier, a preservative, a

– 46 –

chelating agent, a viscomodulator, a tonicifier, a flavorant, a colorant, an odorant, an opacifier, a suspending agent, a binder, a filler, a plasticizer, a thickening agent, a lubricant, and mixtures thereof.

36. The method of claim 35, wherein one of said additives is an antioxidant.

37. The method of claim 36, wherein said antioxidant is selected from the group consisting of butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT).

38. The method of claim 36, wherein said unit dosage form comprises BHA and BHT.

39. The method of claim 33, wherein said unit dosage form is a capsule.

40. The method of claim 39, wherein said capsule is a gelatin capsule.

41. The method of claim 39, wherein the total volume of ingredients in said capsule is 10-1000  $\mu$ l.

42. The method of claim 33, wherein said unit dosage form comprises about 45  $\mu$ g of calcitriol, about 50% MIGLYOL 812, about 50% vitamin E TPGS, BHA, and BHT.